Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
United States
cost-effectiveness
modelling
semaglutide
tirzepatide
Journal
Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
10
01
2023
received:
30
09
2022
accepted:
16
01
2023
medline:
4
4
2023
pubmed:
20
1
2023
entrez:
19
1
2023
Statut:
ppublish
Résumé
To evaluate the long-term cost-effectiveness of tirzepatide (5, 10 and 15 mg doses), a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, versus semaglutide 1.0 mg, an injectable glucagon-like peptide-1 receptor agonist, based on the results of the head-to-head SURPASS-2 trial, from a US healthcare payer perspective. The PRIME Type 2 Diabetes Model was used to make projections of clinical and cost outcomes over a 50-year time horizon. Baseline cohort characteristics, treatment effects and adverse event rates were derived from the 40-week SURPASS-2 trial. Intensification to insulin therapy occurred when HbA1c reached 7.5%, in line with American Diabetes Association recommendations. Direct costs in 2021 US dollars (US$) and health state utilities were derived from published sources. Future costs and clinical benefits were discounted at 3% annually. All three doses of tirzepatide were associated with lower diabetes-related complication rates, improved life expectancy, improved quality-adjusted life expectancy and higher direct costs versus semaglutide. This resulted in incremental cost-effectiveness ratios of US$ 75 803, 58 908 and 48 785 per quality-adjusted life year gained for tirzepatide 5, 10 and 15 mg, respectively, versus semaglutide. Tirzepatide remained cost-effective versus semaglutide over a range of sensitivity analyses. Long-term projections based on the SURPASS-2 trial results indicate that 5, 10 and 15 mg doses of tirzepatide are likely to be cost-effective versus semaglutide 1.0 mg for the treatment of type 2 diabetes in the United States.
Substances chimiques
Hypoglycemic Agents
0
semaglutide
53AXN4NNHX
tirzepatide
OYN3CCI6QE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1292-1300Subventions
Organisme : Eli Lilly and Company
Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020;131:110708.
Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed May 13, 2022.
American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917-928.
Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411-3417.
Giugliano D, Maiorino MI, Bellastella G, Esposito K. Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk. Endocrine. 2018;61(1):23-27.
Boye KS, Lage MJ, Thieu V, Shinde S, Dhamija S, Bae JP. Obesity and glycemic control among people with type 2 diabetes in the United States: a retrospective cohort study using insurance claims data. J Diabetes Complications. 2021;35(9):107975.
Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:100.
Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3):253-261.
Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523.
Eli Lilly and Company Press Release. FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and. Accessed May 12, 2022.
Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.
Academy of Managed Care Pharmacy. AMCP format for formulary submissions. https://www.amcp.org/sites/default/files/2019-12/AMCP_Format%204.1_1219_final.pdf. Accessed May 12, 2022.
Institute for Clinical and Economic Review. Tirzepatide for type 2 diabetes (February 15, 2022). https://icer.org/assessment/diabetes-type-2-2022/#timeline. Accessed July 7, 2022.
Pollock RF, Norrbacka K, Boye KS, Osumili B, Valentine WJ. The PRIME type 2 diabetes model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. J Med Econ. 2022;25(1):393-402.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2013;316(10):1093-1103.
Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47(10):1747-1759.
Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol. 2012;7(3):401-408.
American Diabetes Association. Standard of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83-S96.
Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med. 2007;357(17):1716-1730.
Fadini GP, Feher M, Hansen TK, et al. Switching to degludec from other basal insulins is associated with reduced hypoglycemia rates: a prospective study. Clin Endocrinol Metab. 2019;104(12):5977-5990.
Yang W, Cintina I, Hoerger T, et al. Estimating costs of diabetes complications in people <65 years in the U.S. using panel data. J Diabetes Complications. 2020;34(12):107735.
Yeaw J, Halinan S, Hines D, et al. Direct medical costs for complications among children and adults with diabetes in the US commercial payer setting. Appl Health Econ Health Policy. 2014;12(2):219-230.
Truven Health Analytics/IBM Watson Health. RED BOOK Online. IBM Micromedex [database online]. https://www.micromedexsolutions.com. Accessed May 13, 2022.
WHO Collaborating Centre for Drug Statistic Methodology. A10AE insulins and analogues for injection, long-acting. https://www.whocc.no/atc_ddd_index/?code=A10AE04. Accessed July 7, 2022.
Shao H, Yang S, Fonseca V, Stoecker C, Shi L. Estimating quality of life decrements due to diabetes complications in the United States: the health utility index (HUI) diabetes complication equation. Pharmacoeconomics. 2019;37(7):921-929.
Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17(3):176-183.
Franklin H, Rajan M, Tseng CL, Pogach L, Sinha A, Mph M. Cost of lower-limb amputation in U.S. veterans with diabetes using health services data in fiscal years 2004 and 2010. J Rehabil Res Dev. 2014;51(8):1325-1330.
Candrilli SD, Meyers JL, Boye K, Bae JP. Health care resource utilization and costs during episodes of care for type 2 diabetes mellitus-related comorbidities. J Diabetes Complications. 2015;29(4):529-533.
GLP-1 Receptor Agonist Market Research Report by Product, Drug Class, Route of Administration, Application, Distribution Channel, Region - Global Forecast to. 2027. Cumulative impact of COVID-19. https://www.researchandmarkets.com/reports/5533031/glp-1-receptor-agonist-market-research-report-by?utm. Accessed June 4, 2022.
Ruan Z, Yang L, Shi H, et al. The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 diabetes: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2021;21(2):221-233.
Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. New Engl J Med. 2009;361(18):1736-1747.
Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from Sustain 6 and Pioneer 6. Front Endocrinol. 2021;12:645566.
Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598.
Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824.
Vadher K, Patel H, Mody R, et al. Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison. Diabetes Obes Metab. 2022;24(9):1861-1868.